news
FDA grants Breakthrough Therapy Designation status for acalabrutinib
It has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation...
List view / Grid view
Anti-Cancer Therapeutics
news
Imfinzi wins breakthrough therapy designation
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
news
Patients at risk as UK plans to leave Euratom
The UK's proposed withdrawal from Euratom may threaten the supply of essential medical isotopes, putting cancer patients at risk...
news
Uncovering the cause of immunotherapy resistance in tumours
Scientists have uncovered a key factor in the development of immunotherapy resistance in the case of cutaneous melanoma. This could potentially lead to future improvements in cancer therapy.
news
NICE says Novartis’ and Janssen’s cancer drugs are not cost effective
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
news
Gastric cancer treatment development shifting to mAbs
17 March 2016 | By Victoria White
The dominance of small molecules in the gastric cancer treatment space could be about to give way to monoclonal antibodies, according to GBI Research...
webinar
The Comet Assay – A valuable tool for Cancer Research
6 January 2016 | By Andor
This webinar presents real-world methods and examples of how to monitor and assess DNA damage in these cells using the Comet Assay and an insight into the software used to carry out this analysis...
news
Updated results from Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma announced
22 April 2015 | By Victoria White
Cortice Biosciences has announced interim results a Phase 1/2 trial evaluating TPI 287 plus bevacizumab for the treatment of glioblastoma multiforme...
news
Early findings from KEYTRUDA trial in advanced pleural mesothelioma presented at AACR 2015
20 April 2015 | By Victoria White
The first presentation of data investigating the use of KEYTRUDA in 25 patients with advanced pleural mesothelioma was made at AACR 2015...
news
UMC Utrecht’s new liver cancer treatment approved for use in Europe
14 April 2015 | By Victoria White
A new liver cancer treatment developed by the UMC Utrecht that uses uses radioactive holmium microspheres has received the European CE mark...
news
Inovio’s INO-3112 DNA immunotherapy shows positive preliminary results
9 April 2015 | By Victoria White
INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)...
news
Exelixis’ cabozantinib granted Fast Track designation by FDA for advanced renal cell carcinoma
9 April 2015 | By Victoria White
Exelixis has announced that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma...
news
Advaxis and Merck announce initiation of enrollment in the Phase 1/2 study of ADXS-PSA in combination with KEYTRUDA®
8 April 2015 | By Victoria White
Advaxis and Merck have initiated enrollment in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA and KEYTRUDA in patients with mCRPC...
news
Lion Biotechnologies announces publication of data from clinical study of metastatic cervical cancer patients treated with HPV-TIL
8 April 2015 | By Victoria White
Lion Biotechnologies has announced that data from a study of metastatic cervical cancer patients treated with treated with HPV-TIL has been published...
news
Apceth initiates Phase II clinical trial for pioneering engineered cell therapy to treat gastrointestinal cancer
26 March 2015 | By Victoria White
Apceth has announced the successful completion of the Phase I and initiation of the Phase II with the engineered cell therapy product Agenmestencel-T...
